Tech Company Financing Transactions

Chinook Therapeutics Funding Round

Chinook Therapeutics closed a $106 million funding round on 8/20/2020. Investors included Ally Bridge Group, Apple Tree Partners and Avidity Partners.

Transaction Overview

Company Name
Chinook Therapeutics
Announced On
8/20/2020
Transaction Type
Venture Equity
Amount
$106,000,000
Round
Undisclosed
Investors

Ally Bridge Group

Apple Tree Partners (Sam Hall)

Avidity Partners

EcoR1 Capital Management

Janus Henderson Investors

Monashee Investment Management

Northleaf Capital Partners

OrbiMed

Rock Springs Capital

Samsara BioCapital (Srini Akkaraju)

Sphera Global Health Care Fund

Surveyor Capital

Versant Ventures (Jerel Davis)

Proceeds Purpose
Proceeds from the financing will fund the advancement of the combined company's pipeline, including: Planned phase 2 and phase 3 trials of atrasentan, an investigational selective endothelin receptor antagonist, in development for the treatment of IgA nephropathy and other primary glomerular diseases; Advancement of additional research and discovery programs focused on the treatment of rare, severe chronic kidney diseases.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
887 Great Northern Way 210
Vancouver BC, V5T 4T5
Canada
Phone
Undisclosed
Website
www.chinooktx.com
Email Address
[email protected]
Overview
Chinook Therapeutics is a biotechnology company developing precision medicines for kidney diseases. Kidney diseases are a severe and growing problem worldwide, with a lack of effective treatments often leading to dialysis, transplantation and high costs to health care systems.
Profile
Chinook Therapeutics LinkedIn Company Profile
Social Media
Chinook Therapeutics Company Twitter Account
Company News
Chinook Therapeutics News
Facebook
Chinook Therapeutics on Facebook
YouTube
Chinook Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Eric Dobmeier
  Eric Dobmeier LinkedIn Profile  Eric Dobmeier Twitter Account  Eric Dobmeier News  Eric Dobmeier on Facebook
Chief Medical Officer
Alan Glicklich
  Alan Glicklich LinkedIn Profile  Alan Glicklich Twitter Account  Alan Glicklich News  Alan Glicklich on Facebook
Controller
Ramtin Jamshidi
  Ramtin Jamshidi LinkedIn Profile  Ramtin Jamshidi Twitter Account  Ramtin Jamshidi News  Ramtin Jamshidi on Facebook
Vice President
Renata Oballa
  Renata Oballa LinkedIn Profile  Renata Oballa Twitter Account  Renata Oballa News  Renata Oballa on Facebook
VP - Bus. Development
Thomas Frohlich
  Thomas Frohlich LinkedIn Profile  Thomas Frohlich Twitter Account  Thomas Frohlich News  Thomas Frohlich on Facebook
VP - Bus. Development
Allison Gaw
  Allison Gaw LinkedIn Profile  Allison Gaw Twitter Account  Allison Gaw News  Allison Gaw on Facebook
VP - Finance
Thomas Swallow
  Thomas Swallow LinkedIn Profile  Thomas Swallow Twitter Account  Thomas Swallow News  Thomas Swallow on Facebook
VP - General Counsel
Kirk Schumacher
  Kirk Schumacher LinkedIn Profile  Kirk Schumacher Twitter Account  Kirk Schumacher News  Kirk Schumacher on Facebook
VP - Human Resources
Jodi Jamieson
  Jodi Jamieson LinkedIn Profile  Jodi Jamieson Twitter Account  Jodi Jamieson News  Jodi Jamieson on Facebook
VP - Regulatory Affairs
Valerie Fauvelle
  Valerie Fauvelle LinkedIn Profile  Valerie Fauvelle Twitter Account  Valerie Fauvelle News  Valerie Fauvelle on Facebook

 

 

Browse more venture capital transactions:

Prev: 8/20/2020: Pachyderm venture capital transaction
Next: 8/20/2020: SupportLogic venture capital transaction

 

Share this article

 

About Our VC Transactions Data

We do our best to report on tech company VC transactions. All VC database entries on this site come from a variety of public sources. The information is sourced from VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.